Press release 📈 Stocks 🌍 GLOBAL

Clarivate Releases 2026 Highly Cited Researchers List Featuring 6,802 Names

Clarivate released its 2026 Highly Cited Researchers list, recognizing 6,802 individuals and 7,090 awards while implementing new filters to address research integrity concerns like excessive self-citation.

🕐 1 min read

1 assets impacted (Stocks). Net bias: 0 Bullish, 0 Bearish, 1 Neutral. Strongest signal: CLVT → 2/10 (70% confidence).

📊 Affected Assets (1)

CLVT
Neutral 🤖 70%
📅 Short-term 🌍 GB · Explicit

The annual Highly Cited Researchers 2026 list is Clarivate's flagship Academia & Government product announcement, published November 18, 2026, with no financial figures, guidance or contracts disclosed. As a self-promotional release it maintains brand visibility for the Web of Science franchise but contains nothing that changes the earnings outlook. Directional price effect is unlikely to be material.

Catalysts
  • • Release of Highly Cited Researchers 2026 list on November 18, 2026, recognizing 6,802 individuals from 1,200+ institutions in 62 countries
Risk Factors
  • • No revenue, profit or guidance figures disclosed in the release

🧭 Full analysis of these assets

🎯 Key Takeaways

  • The 2026 list recognizes 6,802 individuals who received a total of 7,090 awards across 62 countries.
  • The United States leads with 2,606 awards, accounting for 37% of the global total.
  • Mainland China holds the second position with 1,484 awards, led by the Chinese Academy of Sciences with 264 awards.
  • Clarivate implemented refined methodology filters to address hyper-prolific authorship and anomalous citation patterns.

📝 Executive Summary

Clarivate Plc has published its annual Highly Cited Researchers 2026 list, identifying 6,802 individuals across 1,200 institutions in 62 countries. The report, which utilizes data from the Web of Science Core Collection, highlights the United States as the global leader with 2,606 awards, followed by Mainland China and the United Kingdom.

❓ FAQ

Does this Clarivate announcement change the investment case?

No. It is the routine annual publication of the Highly Cited Researchers list and includes no financial results, guidance or contracts, so no material effect on the share price is expected.